medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 4

<< Back Next >>

Ann Hepatol 2014; 13 (4)

Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study

García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, González-González JA, Maldonado-Garza HJ, Villarreal-Pérez JZ

Language: English
References: 43
Page: 403-410
PDF size: 130.71 Kb.


ABSTRACT

Aims. To define if there is an imbalance in plasma levels of proinflammatory, fibrogenic and antifibrogenic cytokines in patients with liver cirrhosis (LC) and impaired glucose tolerance (IGT) or diabetes mellitus (DM). Material and methods. We randomly selected 54 out of 100 patients with LC who had normal fasting plasma glucose (FPG) levels. Three groups were formed based on an oral glucose tolerance test (OGTT) results: 18 patients were normal, 18 had IGT, and 18 had DM. Plasma levels of cytokines were measured: TNF- α, soluble tumor necrosis factor receptor 1 (sTNF-R1), leptin, TGF-β1, and hepatocyte growth factor (HGF). Also, fasting plasma insulin (FPI) levels were determined and HOMA2-IR was calculated. Results were compared with those of a control group of 18 patients without liver disease nor DM. Intergroup comparison was performed using non parametric tests. Results. Significantly higher sTNF-R1 and lower TGF-β1 were found in patients with IGT and DM compared to controls. Leptin, HGF, and TNF-α levels showed no significant differences. According to Child-Pugh classification all cytokines levels were impaired in groups B or C as compared to group A. Positive correlations between sTNF-R1 and HOMA2-IR and between leptin and HOMA2-IR were found. Conclusions. IGT and DM were associated with abnormalities of sTNF-R1 and TGF-β1 compared to non cirrhotic controls. Among cirrhotic patients impairment of all cytokines were more marked in advanced liver disease. Finally, sTNF-R1and leptin correlated with IR. These findings suggest that IGT and DM may be causally implicated with liver inflammation process.


REFERENCES

  1. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diab Care 2007; 30: 734-43.

  2. Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, Afeltra A. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev 2006; 22: 274-83

  3. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.

  4. García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE, Vázquez-Elizondo G, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol 2012; 11: 240-8.

  5. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.

  6. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.

  7. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.

  8. Jáquez-Quintana JO, García-Compean, González-González JA, Villarreal Pérez JZ, Lavalle González FJ, Muñoz Espinosa LE, López-Hernández P, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62.

  9. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 21: 280-8.

  10. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005; 22: 24-7.

  11. Taura N, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T, Fukuta, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006; 101: 2752-9.

  12. Marra F, Bertolani C. Adipokines in the liver disease. Hepatology 2009; 50: 957-69.

  13. Gressner AM, Lahme B, Mannherz HG, Polzar B. TGF-betamediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J Hepatol 1997; 26: 1079-92.

  14. Gieling RG, Burt Ad, Mann DA. Fibrosis and cirrhosis reversibility- molecular mechanisms. Clin Liver Dis 2008; 12: 915-37.

  15. Spahr L, Giostra E, Frossard JL, Bresson-Hadni S, Rubbia- Brandt L, Hadengue A. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004; 41: 229-34.

  16. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994; 264: 667-8.

  17. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol 1995; 154: 1307-16.

  18. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-20.

  19. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-80.

  20. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-13.

  21. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-410.

  22. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001; 34: 288-97.

  23. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-71.

  24. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-9.

  25. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, Pasanisi F, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med 2008; 6: 72-8.

  26. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment PharmacolTher 2001; 15: 1667-72.

  27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care 2011; 34(Suppl. 1): S62-S69.

  28. Nguyen DM, El-SeragHB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7.

  29. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophagealvarices. Br J Surg 1973; 60: 646-9.

  30. Kamath PS, Ray Kim W. The Model for End-Stage Liver Disease (MELD). Hepatology 2007; 45: 797-805.

  31. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.

  32. Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36.

  33. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992; 90: 533-6.

  34. Byl B, Roucloux I, Crusiaux A, Dupont E, Devière J. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 1492-7.

  35. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor beta (1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-81.

  36. Yener S, Akinci B, Bayraktar F, Demir T, Akarsu M, Özcan MA, Yalcin M, et al. Serum TGF-β-1 levels in non-alcoholic steatohepatitis. Endocrine Abstracts 2006; 11: 231.

  37. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Genderdependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998; 115: 947-53.

  38. Naveau S, Perlemuter G, Chaillet M, Raynard B, Balian A, Beuzen F, Portier A, et al. Serum leptin in patients with alcoholic liver disease. Alcohol Clin Exp Res 2006; 30: 1422-8.

  39. Greco AV, Mingrone G, Favuzzi A, Capristo E, Gniuli D, Addolorato G, Brunani A, et al. Serum leptin levels in posthepatitis liver cirrhosis. J Hepatol 2000; 33: 38-42.

  40. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-69.

  41. Ockenga J, Tietge UJ, Böker KH, Manns MP, Brabant G, Bahr MJ. Distinct roles of free leptin, bound leptin and soluble leptin receptor during the metabolic-inflammatory response in patients with liver cirrhosis. Aliment Pharmacol Ther 2007; 25: 1301-9.

  42. Yasuda H, Imai E, Shiota A, Fujise N, Morinaga T, Higashio K. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996; 24: 636-42.

  43. Marín Serrano E, Rodríguez Ramos C, Díaz García F, Martín Herrera L, Fernández Gutiérrez del Álamo C, Girón González JA. Hepatocyte growth factor and chronic hepatitis C. Rev Esp Enferm Dig 2010; 102: 365-71.




2020     |     www.medigraphic.com